BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 04, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Velcade bortezomib regulatory update

A panel from the U.K.'s NICE will meet on Nov. 15 to hear an appeal from Johnson & Johnson on an August final appraisal determination (FAD) covering the use of the company's Velcade bortezomib for multiple myeloma (MM). The FAD recommended...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >